Sprint Bioscience (SPRINT) Q1 2026 earnings summary

Executive summary

• Achieved significant progress in R&D programs, expanding medical and commercial value of the portfolio and strengthening financial and operational position.

• Positive preclinical proof-of-concept data in VRK1 and NNMT programs, with NNMT now targeting chronic kidney disease in addition to solid tumors.

• DCPS program advanced with new research supporting its use in AML, and STK25 program maintained focus on MASH after strategic review.

• Established a revolving credit facility, improving capital structure and financial flexibility.

Financial highlights

• Net sales for Q1 2026 were 0 MSEK, down from 14.1 MSEK in Q1 2025.

• Operating result for Q1 2026 was -14.3 MSEK, compared to -5.0 MSEK in Q1 2025.

• Net result after tax for Q1 2026 was -12.9 MSEK, versus -5.6 MSEK in Q1 2025.

• Cash flow from operations was -19.3 MSEK, with cash and equivalents at quarter-end of 108.3 MSEK (18.8 MSEK in Q1 2025).

• Number of shares outstanding at quarter-end: 105,515,538; market capitalization: 251 MSEK.

Outlook and guidance

• No formal forecast provided for future periods.